You are viewing a single comment's thread.

view the rest of the comments →

0
4

[–] individualin1984 0 points 4 points (+4|-0) ago 

“We are not a diagnostic tool, and we will never be a diagnostic tool,” said FDNA CEO Dekel Gelbman.

Drawing that bright line between Face2Gene and “a diagnostic tool” allows FDNA to stay compliant with FDA regulations governing mobile medical apps while avoiding some of the regulatory burden associated with smartphone-based diagnostic tools.

Here we have another example of how a great technology has to dance around the FDA rules. And even doing this the FDA will still probably shut them down for being too close to a diagnostic tool.

0
3

[–] Damnpasswords 0 points 3 points (+3|-0) ago 

Until they start charging $1000 dollars per download and cut the FDA in. Remember the asthma medicine from the fifties that a company recently bribed the FDA for its patent rights?